INDIANAPOLIS, March 17 /PRNewswire-FirstCall/ -- Eli Lilly and Company today issued a statement and details regarding the stolen company products from its distribution operations in Enfield, Connecticut on Sunday, March 14.
"Since early Sunday morning, Lilly has taken quick and appropriate actions to ensure the safety of our medicines," said Dr. Fionnuala M. Walsh, Lilly's senior vice president of global quality. "The U.S. pharmaceutical distribution system is tightly controlled and monitored, making it extremely difficult for stolen product to make it to patients through legitimate channels. However, we will continue to work closely with local and federal law enforcement authorities, the FDA, and our distribution partners to maintain the integrity of our drug supply chain."
These medicines require a prescription for purchase. Consumers should purchase Lilly products only from well-established and reputable retailers. Lilly recommends that consumers always inspect the product and label for signs of tampering before opening.
To assist the FDA and the law enforcement agencies in their investigation, Lilly stopped distributing product with the affected lot numbers on Monday, March 15, 2010.
For medical or other related inquiries about this matter, contact Lilly at 1-800-LILLYRX (1-800-545-5979).
About Eli Lilly and Company
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information -- for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com. C-LLY
(Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO )
Photo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO
PRN Photo Desk, photodesk@prnewswire.comEli Lilly and Company
